Search

Your search keyword '"Sutton, Maria Undurraga"' showing total 13 results
Start Over Author "Sutton, Maria Undurraga"
13 results on '"Sutton, Maria Undurraga"'

1. CML-047 Post Hoc Analysis of Responses to Ponatinib in Patients With Chronic-Phase Chronic Myeloid Leukemia (CP-CML) by Baseline BCR::ABL1 Level and Baseline Mutation Status in the OPTIC Trial

Author

Deininger, Michael, Apperley, Jane, Arthur, Christopher Kevin, Chuah, Charles, Hochhaus, Andreas, de Lavallade, Hugues, Lipton, Jeffrey, Lomaia, Elza, McCloskey, James, Maness, Lori, Mauro, Michael, Moraghi, Beatriz, Pavlovsky, Carolina, Rosti, Gianantonio, Rousselot, Philippe, Sutton, Maria Undurraga, Ren, Xiaowei, Vorog, Alexander, and Cortes, Jorge

Published
2022
Full Text
View/download PDF

2. POSTER: CML-313 Post Hoc Analysis of Patient Responses by T315I Mutation Status From the 3-Year Update of the OPTIC Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib

Author

Cortes, Jorge, primary, Deininger, Michael, additional, Lomaia, Elza, additional, Moiraghi, Beatriz, additional, Sutton, Maria Undurraga, additional, Pavlovsky, Carolina, additional, Chuah, Charles, additional, Sacha, Tomasz, additional, Lipton, Jeffrey H., additional, McCloskey, James, additional, Rousselot, Philippe, additional, Rosti, Gianantonio, additional, de Lavallade, Hugues, additional, Rojas, Christine, additional, Turkina, Anna, additional, Talpaz, Moshe, additional, Mauro, Michael, additional, Lu, Vickie, additional, Vorog, Alexander, additional, and Apperley, Jane, additional

Published
2023
Full Text
View/download PDF

3. CML-313 Post Hoc Analysis of Patient Responses by T315I Mutation Status From the 3-Year Update of the OPTIC Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib

Author

Cortes, Jorge, primary, Deininger, Michael, additional, Lomaia, Elza, additional, Moiraghi, Beatriz, additional, Sutton, Maria Undurraga, additional, Pavlovsky, Carolina, additional, Chuah, Charles, additional, Sacha, Tomasz, additional, Lipton, Jeffrey H., additional, McCloskey, James, additional, Rousselot, Philippe, additional, Rosti, Gianantonio, additional, de Lavallade, Hugues, additional, Rojas, Christine, additional, Turkina, Anna, additional, Talpaz, Moshe, additional, Mauro, Michael, additional, Lu, Vickie, additional, Vorog, Alexander, additional, and Apperley, Jane, additional

Published
2023
Full Text
View/download PDF

4. CML-319 Molecular Response of ≤10% BCR::ABL1IS Is Predictive of Positive Outcomes in Patients With Treatment-Resistant Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Treated With Ponatinib From the Phase 2 OPTIC Trial

Author

Apperley, Jane, primary, Cortes, Jorge, additional, Jabbour, Elias, additional, Hochhaus, Andreas, additional, Hughes, Timothy, additional, Chuah, Charles, additional, de Lavallade, Hugues, additional, Deininger, Michael, additional, Lipton, Jeffrey H., additional, Lomaia, Elza, additional, Maness, Lori, additional, Mauro, Michael, additional, McCloskey, James, additional, Moiraghi, Beatriz, additional, Pavlovsky, Carolina, additional, Rojas, Christine, additional, Rousselot, Philippe, additional, Sacha, Tomasz, additional, Talpaz, Moshe, additional, Turkina, Anna, additional, Sutton, Maria Undurraga, additional, Ren, Xiaowei, additional, Vorog, Alexander, additional, and Rosti, Gianantonio, additional

Published
2023
Full Text
View/download PDF

5. POSTER: CML-319 Molecular Response of ≤10% BCR::ABL1IS Is Predictive of Positive Outcomes in Patients With Treatment-Resistant Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Treated With Ponatinib From the Phase 2 OPTIC Trial

Author

Apperley, Jane, primary, Cortes, Jorge, additional, Jabbour, Elias, additional, Hochhaus, Andreas, additional, Hughes, Timothy, additional, Chuah, Charles, additional, de Lavallade, Hugues, additional, Deininger, Michael, additional, Lipton, Jeffrey H., additional, Lomaia, Elza, additional, Maness, Lori, additional, Mauro, Michael, additional, McCloskey, James, additional, Moiraghi, Beatriz, additional, Pavlovsky, Carolina, additional, Rojas, Christine, additional, Rousselot, Philippe, additional, Sacha, Tomasz, additional, Talpaz, Moshe, additional, Turkina, Anna, additional, Sutton, Maria Undurraga, additional, Ren, Xiaowei, additional, Vorog, Alexander, additional, and Rosti, Gianantonio, additional

Published
2023
Full Text
View/download PDF

6. Three-Year Update from the Optic Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib

Author

Cortes, Jorge E., primary, Deininger, Michael W., additional, Lomaia, Elza, additional, Moiraghi, Beatriz, additional, Sutton, Maria Undurraga, additional, Pavlovsky, Carolina, additional, Chuah, Charles, additional, Sacha, Tomasz, additional, Lipton, Jeffrey H., additional, McCloskey, James, additional, Hochhaus, Andreas, additional, Rousselot, Philippe, additional, Rosti, Gianantonio, additional, de Lavallade, Hugues, additional, Rojas, Christine, additional, Turkina, Anna, additional, Maness, Lori, additional, Talpaz, Moshe, additional, Mauro, Michael, additional, Lu, Vickie, additional, Vorog, Alexander, additional, and Apperley, Jane F., additional

Published
2022
Full Text
View/download PDF

7. Molecular Response of ≤10% BCR::ABL1IS Is Predictive of Positive Outcomes in Treatment-Resistant Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Ponatinib from the Phase 2 Optic Trial

Author

Apperley, Jane F., primary, Cortes, Jorge E., additional, Jabbour, Elias, additional, Hochhaus, Andreas, additional, Hughes, Timothy, additional, Chuah, Charles, additional, de Lavallade, Hugues, additional, Deininger, Michael W., additional, Lipton, Jeffrey H., additional, Lomaia, Elza, additional, Maness, Lori, additional, Mauro, Michael, additional, McCloskey, James, additional, Moiraghi, Beatriz, additional, Pavlovsky, Carolina, additional, Rojas, Christine, additional, Rousselot, Philippe, additional, Sacha, Tomasz, additional, Talpaz, Moshe, additional, Turkina, Anna, additional, Sutton, Maria Undurraga, additional, Ren, Xiaowei, additional, Vorog, Alexander, additional, and Rosti, Gianantonio, additional

Published
2022
Full Text
View/download PDF

8. Poster: CML-047 Post Hoc Analysis of Responses to Ponatinib in Patients With Chronic-Phase Chronic Myeloid Leukemia (CP-CML) by Baseline BCR::ABL1 Level and Baseline Mutation Status in the OPTIC Trial

Author

Deininger, Michael, primary, Apperley, Jane, additional, Arthur, Christopher Kevin, additional, Chuah, Charles, additional, Hochhaus, Andreas, additional, de Lavallade, Hugues, additional, Lipton, Jeffrey, additional, Lomaia, Elza, additional, McCloskey, James, additional, Maness, Lori, additional, Mauro, Michael, additional, Moraghi, Beatriz, additional, Pavlovsky, Carolina, additional, Rosti, Gianantonio, additional, Rousselot, Philippe, additional, Sutton, Maria Undurraga, additional, Ren, Xiaowei, additional, Vorog, Alexander, additional, and Cortes, Jorge, additional

Published
2022
Full Text
View/download PDF

9. CML-129: OPTIC Primary Analysis: A Dose-Optimization Study of 3 Starting Doses of Ponatinib (PON)

Author

Cortes, Jorge E., primary, Apperley, Jane F., additional, Lomaia, Elza, additional, Moiraghi, Beatriz, additional, Sutton, Maria Undurraga, additional, Pavlovsky, Carolina, additional, Chuah, Charles, additional, Sacha, Tomasz, additional, Lipton, Jeffrey H., additional, McCloskey, James, additional, Hochhaus, Andreas, additional, Rousselot, Philippe, additional, Rosti, Gianantonio, additional, De Lavallade, Hugues, additional, Mauro, Michael J., additional, Hall, Tracey, additional, Lu, Vickie, additional, Srivastava, Shouryadeep, additional, and Deininger, Michael W., additional

Published
2021
Full Text
View/download PDF

10. Poster: CML-129: OPTIC Primary Analysis: A Dose-Optimization Study of 3 Starting Doses of Ponatinib (PON)

Author

Cortes, Jorge E., primary, Apperley, Jane F., additional, Lomaia, Elza, additional, Moiraghi, Beatriz, additional, Sutton, Maria Undurraga, additional, Pavlovsky, Carolina, additional, Chuah, Charles, additional, Sacha, Tomasz, additional, Lipton, Jeffrey H., additional, McCloskey, James, additional, Hochhaus, Andreas, additional, Rousselot, Philippe, additional, Rosti, Gianantonio, additional, De Lavallade, Hugues, additional, Mauro, Michael J., additional, Hall, Tracey, additional, Lu, Vickie, additional, Srivastava, Shouryadeep, additional, and Deininger, Michael W., additional

Published
2021
Full Text
View/download PDF

11. Oral Abstract: CML-129: OPTIC Primary Analysis: A Dose-Optimization Study of 3 Starting Doses of Ponatinib (PON)

Author

Cortes, Jorge E., primary, Apperley, Jane F., additional, Lomaia, Elza, additional, Moiraghi, Beatriz, additional, Sutton, Maria Undurraga, additional, Pavlovsky, Carolina, additional, Chuah, Charles, additional, Sacha, Tomasz, additional, Lipton, Jeffrey H., additional, McCloskey, James, additional, Hochhaus, Andreas, additional, Rousselot, Philippe, additional, Rosti, Gianantonio, additional, De Lavallade, Hugues, additional, Mauro, Michael J., additional, Hall, Tracey, additional, Lu, Vickie, additional, Srivastava, Shouryadeep, additional, and Deininger, Michael W., additional

Published
2021
Full Text
View/download PDF

12. CML-114: Interim Analysis from the OPTIC Trial - A Dose-Ranging Study of 3 Starting Doses of Ponatinib

Author

Cortes, Jorge, primary, Lomaia, Elza, additional, Turkina, Anna, additional, Moiraghi, Beatriz, additional, Sutton, Maria Undurraga, additional, Pavlovsky, Carolina, additional, Rojas, Christine, additional, Chuah, Charles, additional, Arthur, Christopher, additional, Apperley, Jane, additional, Kim, Dong-Wook, additional, Hochhaus, Andreas, additional, Rousselot, Philippe, additional, Rosti, Gianantonio, additional, Mauro, Michael, additional, Lipton, Jeffrey, additional, Naranjo, Daniel, additional, Liu, Guohui, additional, Srivastava, Shouryadeep, additional, and Deininger, Michael, additional

Published
2020
Full Text
View/download PDF

13. Molecular Response of ≤10% BCR::ABL1ISIs Predictive of Positive Outcomes in Treatment-Resistant Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Ponatinib from the Phase 2 Optic Trial

Author

Apperley, Jane F., Cortes, Jorge E., Jabbour, Elias, Hochhaus, Andreas, Hughes, Timothy, Chuah, Charles, de Lavallade, Hugues, Deininger, Michael W., Lipton, Jeffrey H., Lomaia, Elza, Maness, Lori, Mauro, Michael, McCloskey, James, Moiraghi, Beatriz, Pavlovsky, Carolina, Rojas, Christine, Rousselot, Philippe, Sacha, Tomasz, Talpaz, Moshe, Turkina, Anna, Sutton, Maria Undurraga, Ren, Xiaowei, Vorog, Alexander, and Rosti, Gianantonio

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results